Cargando…
Comparing the longer-term effectiveness of a single dose of the Pfizer-BioNTech and Oxford-AstraZeneca COVID-19 vaccines across the age spectrum
BACKGROUND: A single dose strategy may be adequate to confer population level immunity and protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, especially in low- and middle-income countries where vaccine supply remains limited. We compared the effectiveness of...
Autores principales: | Kaura, Amit, Trickey, Adam, Shah, Anoop S V, Benedetto, Umberto, Glampson, Ben, Mulla, Abdulrahim, Mercuri, Luca, Gautama, Sanjay, Costelloe, Ceire E, Goodman, Ian, Redhead, Julian, Saravanakumar, Kavitha, Mayer, Erik, Mayet, Jamil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918854/ https://www.ncbi.nlm.nih.gov/pubmed/35295900 http://dx.doi.org/10.1016/j.eclinm.2022.101344 |
Ejemplares similares
-
Thrombocytopenic purpura with AstraZeneca but not Pfizer-BioNTech COVID-19 vaccine
Publicado: (2021) -
AstraZeneca and Pfizer-BioNTech COVID-19 vaccines: AEs in South Korea
Publicado: (2021) -
Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups
por: Whitaker, Heather J., et al.
Publicado: (2022) -
Comparison of antibody responses before and after booster doses with the Pfizer-BioNTech or Oxford–AstraZeneca vaccines in healthcare workers in Thailand
por: Phumisantiphong, Uraporn, et al.
Publicado: (2023) -
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
por: Eyre, David W., et al.
Publicado: (2021)